With the recent attention to the importance of evidence-based medicine in psychiatry, a number of treatment guidelines have been published. This survey investigated prescribing pattern and predictors for guideline disconcordance in the acute treatment of bipolar depression across mainland China. Pharmacological treatments of 1078 patients with bipolar depression were examined. Guidelines disconcordance was determined by comparing the medication(s) patients were prescribed with the recommendation(s) in the guidelines of the Canadian Network for Mood and Anxiety Treatments. Predictors for guidelines discordance were analyzed with logistic regression. Of the 1078 patients, 50.2% patients were treated against treatment guidelines recommendations. The patients who were treated in general hospitals (OR = 1.53, 95% CI 1.18–1.97), with a depressive episode (OR = 1.67, 95% CI 1.27–2.19) and an older age at first onset (OR = 1.62, 95% CI 1.15–2.28) were more likely to receive guideline-disconcordant treatment than their counterparts. In contrast, the patients with current mental comorbidity, an older age at study entry, a longer duration of disease, and more frequent episodes in past year were less likely to receive guideline-disconcordant treatments than their counterparts with an OR of 0.43 (95% CI 0.24–0.77), 0.52 (95CI% 0.36–0.75), 0.48 (95% CI 0.36–0.65), and 0.50 (95% CI 0.38–0.64), respectively. Our finding suggested the disconcordance with treatment guidelines in patients with an acute bipolar depression is common under naturalistic conditions in mainland China, and the predicting factors correlated with guidelines disconcordance include both psychiatrist-specific (clinicians from general hospitals) and patient-specific features (a depressive episode at first onset, no current co-morbidity with mental disorders, a younger age at study entry, an older age at first onset, shorter duration of disease, and non-frequent episodes in past year).
References
[1]
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543–552.
[2]
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, et al. (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68: 241–251.
[3]
Osby U, Brandt L, Correia N, Ekbom A, Sparén P (2001) Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 58: 844–850.
[4]
Kupfer DJ (2005) The increasing medical burden in bipolar disorder. JAMA 293: 2528–2530.
[5]
Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, et al. (2003) Costs of bipolar disorder. Pharmacoeconomics 21: 601–622.
[6]
Dilsaver SC (2011) An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 129: 79–83.
[7]
American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (Suppl. 4)1–50.
[8]
National Collaborating Center for Mental Health (2006) Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Second Care. Leicester (UK): British Psychological Society.
[9]
Shen QJ, Liu TB, Zhang HY, Ma X, Wang GH, et al.. (2007) Practice guideline for prevention and treatment of bipolar disorder (in Chinese). Beijing (China): Chinese Medical Association.
[10]
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, et al. (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85–116.
[11]
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, et al. (2010) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11: 81–109.
[12]
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, et al. (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14: 154–219.
[13]
Mok YM, Chan HN, Chee KS, Chua TE, Lim BL, et al. (2011) Ministry of Health clinical practice guidelines: bipolar disorder. Singapore Med J 52: 914–918.
[14]
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, et al. (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord15: 1–44.
[15]
Dennehy EB, Suppes T, Rush AJ, Miller AL, Trivedi MH, et al. (2005) Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychol Med 35: 1695–1706.
[16]
Bauer MS, Biswas K, Kilbourne AM (2009) Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry 166: 1244–1250.
[17]
Geddes JR, Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381: 1672–1682.
[18]
Dennehy EB, Bauer MS, Perlis RH, Kogan JN, Sachs GS (2007) Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull 40: 72–84.
[19]
Perlis RH (2007) Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr Med Res Opin 23: 467–475.
[20]
Smith TE, Levine SB, Hampel J (2008) A successful effort to improve adherence to treatment guidelines for bipolar disorder. Harv Rev Psychiatry 16: 210–213.
[21]
Alt？nba？ K, Smith D, Oral ET (2011) Adherence to Turkish psychiatric association guideline for bipolar depression treatment in a specialized mood disordersoutpatient unit. Psychiatr Danub 23: 189–193.
[22]
Samalin L, Guillaume S, Auclair C, Llorca PM (2011) Adherence to guidelines by French psychiatrists in their real world of clinical practice. J Nerv Ment Dis 199: 239–243.
[23]
Paterniti S, Bisserbe JC (2013) Pharmacotherapy for bipolar disorder and concordance with treatment guidelines: survey of a general population sample referred to a tertiary care service. BMC Psychiatry 13: 211.
[24]
Xiang YT, Zhang L, Wang G, Hu C, Ungvari GS, et al. (2013) Sociodemographic and clinical features of bipolar disorder patients misdiagnosed with major depressive disorder in China. Bipolar Disord 15: 199–205.
[25]
Xiang YT, Hu C, Wang G, Zheng QW, Fang YR, et al. (2012) Prescribing patterns of antidepressants, antipsychotics and mood stabilizers in bipolar patients misdiagnosed with major depressive disorder in China. Hum Psychopharmacol 27: 626–631.
[26]
Bukh JD, Bock C, Vinberg M, Gether U, Kessing LV (2011) Differences between early and late onset adult depression. Clin Pract Epidemiol Ment Health 7: 140–147.
[27]
Fang Y, Wang Z (2011) Current status and future trends in clinical research of bipolar disorder (in Chinese). Shanghai Archives of Psychiatry 23: 12–16.
[28]
Azorin JM, Angst J, Gamma A, Bowden CL, Perugi G, et al. (2012) Identifying features of bipolarity in patients with first-episode postpartum depression: findings from the international BRIDGE study. J Affect Disord 136: 710–715.
[29]
Masi G, Mucci M, Pfanner C, Berloffa S, Magazù A, et al. (2012) Developmental pathways for different subtypes of early-onset bipolarity in youths. J Clin Psychiatry 73: 1335–1341.
[30]
Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, et al. (2004) Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol 24: 512–520.
[31]
Gao K, Kemp DE, Conroy C, Ganocy SJ, Findling RL, et al. (2010) Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients. Int J Clin Pract 64: 336–344.
[32]
Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, et al. (2004) Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 161: 2222–2229.
[33]
Gao K, Wang Z, Chen J, Kemp DE, Chan PK, et al. (2013) Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J Affect Disord 148: 256–264.
[34]
Hirschfeld RM, Lewis L, Vornik LA (2003) Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 64: 161–174.
[35]
Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, et al. (2007) Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 58: 85–91.
[36]
Carta MG, Aguglia E, Balestrieri M, Calabrese JR, Caraci F, et al. (2012) The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. J Affect Disord 136: 775–780.
[37]
Greil W, H？berle A, Haueis P, Grohmann R, Russmann S (2012) Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 136: 534–542.
[38]
Goldberg JF, Brooks JO 3rd, Kurita K, Hoblyn JC, Ghaemi SN, et al. (2009) Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70: 155–162.
[39]
Lorenzo LS, Vázquez GH, Zaratiegui RM, Tondo L, Baldessarini RJ (2012) Characteristics of bipolar disorder patients given antidepressants. Hum Psychopharmacol 27: 486–491.
[40]
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, et al. (2013) The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. Am J Psychiatry 170: 1249–1262.
[41]
Vieta E, Valentí M (2013) Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 27: 515–529.
[42]
Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, et al. (2010) Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 71: 1176–1186.
